|
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 18076/20274 (89%)
Visitors : 4699249
Online Users : 501
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
https://ir.cnu.edu.tw/handle/310902800/34639
|
標題: | Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer |
作者: | Kan, Wei-Chih Hsieh, Kun-Lin Chen, Yi-Chen Ho, Chung Han Hong, Chon-Seng Chiang, Chun-Yen Wu, Nan-Chun Chen, Michael Shih, Jhih-Yuan Chen, Zhih-Cherng Chang, Wei-Ting |
貢獻者: | Chi Mei Hospital Chung Hua University Chi Mei Hospital National Cheng Kung University Chi Mei Hospital Department of Pharmacy, Chia Nan University of Pharmacy & Science Chi Mei Hospital Chung Hua University Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science Southern Taiwan University of Science & Technology National Cheng Kung University |
關鍵字: | androgen-deprivation therapy hormone agonists serum testosterone risk men disease orchiectomy atherosclerosis suppression level |
日期: | 2022 |
上傳時間: | 2023-12-11 14:02:01 (UTC+8) |
出版者: | LIPPINCOTT WILLIAMS & WILKINS |
摘要: | Purpose: Androgen deprivation therapy (ADT) includes bilateral orchiectomy or long-acting gonadotropin-releasing hormone (GnRH) agonists/antagonists. It remains controversial with respect to ADT associated cardiovascular outcomes. Hereby, we compared the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with prostate cancer receiving either surgical castration or GnRH therapies. Materials and Methods: Using the Taiwan Cancer Registry and Taiwan's National Health Insurance Research Database, we identified 8,413 patients receiving GnRH therapies compared with 694 receiving surgical castration from 2008 to 2017. The median followup duration was 3 years. Results: The crude incidences of 3-year mortality and MACCEs were 19.90% vs 26.51% and 8.23% vs 8.65% in patients receiving GnRH therapies or surgical castration, respectively. After adjusting for age, cancer stage and comorbidities, despite no significant differences in MACCEs between groups there was a slight increase in the incidence of acute myocardial infarction (AMI) in patients receiving surgical castration compared with those receiving GnRH therapies. The mortality adjusted hazard ratios of MACCEs and AMI among patients receiving surgical castration were 1.11- and 1.8-fold higher than those receiving GnRH therapies. Notably, in subgroup analysis regarding cancer stage, patients with cancer stage IV showed the most significantly increasing risk of AMI in those receiving surgical castration compared with GnRH therapies. Conclusions: Collectively, we indicated an increased risk of AMI in patients with prostate cancer, especially in patients receiving surgical castration rather than those receiving GnRH therapies. Our findings highlight concerns regarding the cardiac safety of surgical castration compared with GnRH therapies. |
關聯: | JOURNAL OF UROLOGY, v.207, Issue 4, pp.841-850 |
Appears in Collections: | [藥學系(所)] 期刊論文 [保健營養系(所) ] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
index.html | | 0Kb | HTML | 246 | View/Open |
|
All items in CNU IR are protected by copyright, with all rights reserved.
|